Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 9/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.40 |
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | NCF1 | P14598 | 1/20 | 0.40 |
| ▸ | CHKA | P35790 | 1/20 | 0.40 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4224736 | 0.99 | HRH3 (0.42) | HRH3KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL4208363 | 0.83 | KDM1A (0.51) | HRH3KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL4228606 | 0.82 | HRH3 (0.49) | HRH3KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL4205328 | 0.81 | ALDH1A1 (0.43) | HRH3KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL4576616 | 0.79 | HRH3 (0.46) | HRH3KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL4236471 | 0.79 | KDM1A (0.50) | KDM4EMEN1ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL4125464 | 0.75 | TSHR (0.54) | HRH3MEN1ALDH1A1KMT2ACYP2D6 | |
| SCHEMBL2629477 | 0.75 | CYP2D6 (0.57) | MEN1ALDH1A1KMT2ACYP2D6CYP3A4 | |
| SCHEMBL4213604 | 0.75 | KDM1A (0.35) | HRH3KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL4233451 | 0.75 | CXCR4 (0.43) | HRH3KDM4EMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871210-B2 | Chemokine receptor antagonists and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-10-28 | — | — | US | disclosed |
| US-20140072576-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-13 | — | — | US | disclosed |
| US-8614323-B2 | Chemokine receptor antagonists and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-12-24 | — | — | US | disclosed |
| EP-2657235-A1 | Compound containing basic group and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-30 | — | — | EP | disclosed |
| EP-1942108-B1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO (JP) | 2013-09-04 | — | — | EP | disclosed |
| EP-2042503-B1 | COMPOUND HAVING ACIDIC GROUP WHICH MAY BE PROTECTED, AND USE THEREOF | ONO PHARMACEUTICAL CO (JP) | 2013-01-30 | — | — | EP | disclosed |
| US-20120328627-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-12-27 | — | — | US | disclosed |
| US-8318931-B2 | Chemokine receptor antagonists and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-11-27 | — | — | US | disclosed |
| US-8293896-B2 | — | — | 2012-10-23 | — | — | US | disclosed |
| US-20090118279-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD., (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-2042503-A1 | COMPOUND HAVING ACIDIC GROUP WHICH MAY BE PROTECTED, AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-04-01 | — | — | EP | disclosed |
| EP-1942108-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140072576-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF | CXCR4, CXCR1, CXCR3 | HRH3 314/4885KDM4E 4377/4885MEN1 3160/4885 |
| US-20090118279-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | CXCR4, CXCR1, CXCR3 | HRH3 185/4885KDM4E 3862/4885MEN1 2513/4885 |
| US-20120328627-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF | CXCR4, CXCR1, CXCR3 | HRH3 314/4885KDM4E 4377/4885MEN1 3160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.